

Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

Johannes Lübke,¹ Alicia Schmid,¹ Deborah Christen,^{2,3} Hanneke N. G. Oude Elberink,⁴ Lambert F. R. Span,⁵ Marek Niedoszytko,⁶ Aleksandra Gorska,⁶ Magdalena Lange,⁷ Karoline V. Gleixner,^{8,9} Emir Hadzijušufovic,⁸⁻¹⁰ Alex Stefan,¹¹ Irena Angelova-Fischer,¹² Roberta Zanotti,¹³ Massimiliano Bonifacio,¹³ Patrizia Bonadonna,¹⁴ Khalid Shoumariyeh,^{15,16} Nikolas von Bubnoff,¹⁵⁻¹⁷ Sabine Müller,¹⁸ Cecelia Perkins,¹⁹ Chiara Elena,²⁰ Luca Malcovati,²⁰ Hans Hagglund,²¹ Mattias Mattsson,²¹ Roberta Parente,²² Judit Varkonyi,²³ Anna Belloni Fortina,²⁴ Francesca Caroppo,²⁴ Knut Brockow,²⁵ Alexander Zink,²⁵ Christine Breynaert,²⁶ Toon Leven,²⁶ Akif Selim Yavuz,²⁷ Michael Doubek,²⁸ Vito Sabato,²⁹ Tanja Schug,³⁰ Karin Hartmann,^{31,32} Massimo Triggiani,²² Jason Gotlib,¹⁹ Olivier Hermine,³³ Michel Arock,³⁴ Hanneke C. Kluin-Nelemans,⁵ Jens Panse,^{2,3} Wolfgang R. Sperr,^{8,9} Peter Valent,^{8,9} Andreas Reiter,¹ and Juliana Schwaab¹

¹Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany; ²Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany; ³Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf, Aachen, Germany; ⁴Department of Allergy and ⁵Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; ⁶Department of Allergy, Medical University of Gdańsk, Gdańsk, Poland; ⁷Department of Dermatology, Venereology and Allergy, Medical University of Gdańsk, Gdańsk, Poland; ⁸Division of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; ⁹Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; ¹⁰Department/University Clinic for Companion Animals and Horses, Internal Medicine Small Animals, University Clinic for Small Animals, University of Veterinary Medicine, Vienna, Austria; ¹¹University Clinic for Hematology and Oncology and ¹²Department of Dermatology and Venereology, Allergy Center, Kepler University Hospital, Johannes Kepler University, Linz, Austria; ¹³Department of Medicine, Section of Hematology and ¹⁴Allergy Unit, Verona University Hospital, Verona, Italy; ¹⁵Department of Medicine I, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; ¹⁶German Cancer Consortium (DKTK), partner site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany; ¹⁷Department of Hematology and Oncology, Medical Center, University of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; ¹⁸Department of Dermatology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; ¹⁹Stanford Cancer Institute, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA; ²⁰Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; ²¹Division of Hematology, Department of Medical Sciences Uppsala University, Uppsala, Sweden; ²²Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy; ²³Department of Hematology, Semmelweis University, Budapest, Hungary; ²⁴Department of Medicine, Pediatric Dermatology Unit, University of Padova, Padova, Italy; ²⁵Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany; ²⁶KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group and MASTeL, University Hospitals Leuven, Leuven, Belgium; ²⁷Division of Hematology, Istanbul Medical School, University of Istanbul, Istanbul, Turkey; ²⁸Department of Internal Medicine - Hematology and Oncology, University Hospital Brno & Faculty of Medicine, Masaryk University, Brno, Czech Republic; ²⁹Department of Immunology-Allergy-Rheumatology, Faculty of Medicine and Health Sciences, University of Antwerp and Antwerp University Hospital, Antwerpen, Belgium; ³⁰Department of Dermatology and Venereology, University Hospital Graz, Graz, Austria; ³¹Division of Allergy, Department of Dermatology and ³²Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland; ³³French Reference Center for Mastocytosis, Hôpital Necker, Assistance Publique Hôpitaux de Paris, Imagine Institute, University Paris Descartes, Paris, France; and ³⁴French Reference Center for Mastocytosis, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, University Paris Sorbonne, Paris, France

Key Points

- Serum chemistry profiling is of diagnostic and prognostic relevance based on easily accessible parameters.
- Serum chemistry markers help to assess and quantify organ damage.

Certain laboratory abnormalities correlate with subvariants of systemic mastocytosis (SM) and are often prognostically relevant. To assess the diagnostic and prognostic value of individual serum chemistry parameters in SM, 2607 patients enrolled within the European Competence Network on Mastocytosis and 575 patients enrolled within the German Registry on Eosinophils and Mast Cells were analyzed. For screening and diagnosis of SM, tryptase was identified as the most specific serum parameter. For differentiation between indolent and advanced SM (AdvSM), the following serum parameters were most relevant: tryptase, alkaline phosphatase, β 2-microglobulin, lactate dehydrogenase (LDH), albumin, vitamin B12, and C-reactive protein ($P < .001$). With regard to subvariants of AdvSM, an elevated LDH of ≥ 260 U/L was associated with multilineage expansion (leukocytosis, $r = 0.37$, $P < .001$; monocytosis, $r = 0.26$, $P < .001$) and the presence of an associated myeloid neoplasm ($P < .001$), whereas

Submitted 24 January 2024; accepted 18 March 2024; prepublished online on *Blood Advances* First Edition 9 April 2024; final version published online 5 June 2024.
<https://doi.org/10.1182/bloodadvances.2024012756>.

The data sets used and/or analyzed during this study are available on request from the corresponding author, Juliana Schwaab (juliana.schwaab@medma.uni-heidelberg.de).

The full-text version of this article contains a data supplement.

© 2024 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

tryptase levels were highest in mast cell leukemia (MCL) vs non-MCL (308 μ g/L vs 146 μ g/L, $P = .003$). Based on multivariable analysis, the hazard-risk weighted assignment of 1 point to LDH (hazard ratio [HR], 2.1; 95% confidence interval [CI], 1.1-4.0; $P = .018$) and 1.5 points each to β 2-microglobulin (HR, 2.7; 95% CI, 1.4-5.4; $P = .004$) and albumin (HR, 3.3; 95% CI, 1.7-6.5; $P = .001$) delineated a highly predictive 3-tier risk classification system (0 points, 8.1 years vs 1 point, 2.5 years; ≥ 1.5 points, 1.7 years; $P < .001$). Moreover, serum chemistry parameters enabled further stratification of patients classified as having an International Prognostic Scoring System for Mastocytosis-AdvSM1/2 risk score ($P = .027$). In conclusion, serum chemistry profiling is a crucial tool in the clinical practice supporting diagnosis and prognostication of SM and its subvariants.

Introduction

Systemic mastocytosis (SM) is characterized by expansion and accumulation of neoplastic mast cells (MCs) in various organ systems, frequently including the bone marrow (BM), skin, and the gastrointestinal tract. According to the World Health Organization (WHO) 2022 and the International Consensus Criteria (ICC) 2022, main subvariants of SM are indolent SM (ISM), smoldering SM (SSM), and advanced SM (AdvSM). BM mastocytosis (BMM) has previously been defined as a provisional subvariant of ISM and is now recognized as a separate variant of SM by the WHO. BMM is characterized by a limited degree of BM infiltration, absence of skin lesions, normal or slightly elevated serum tryptase levels, older age, male predominance, and a strong association with severe allergic reactions to hymenoptera sting. AdvSM comprises aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN)/myeloid neoplasm, and MC leukemia (MCL). In AdvSM, the majority of patients present with signs of organ damage (C-findings), particularly cytopenias and signs of liver involvement.¹⁻⁴ A somatic point mutation in *KIT* at codon 816 (*KIT* D816V) is identified in $>80\%$ of all patients with SM.⁵⁻⁸ Although patients with indolent forms have a normal life expectancy, patients with AdvSM have a poor prognosis with shortened survival times ranging between 1 and 4 years.⁹⁻¹⁴

Serum chemistry parameters have been variably included in recently published risk-stratification scoring systems for SM. Besides serum tryptase, which is known for its outstanding value for screening and diagnosis, hypoalbuminemia and elevated alkaline phosphatase (AP) are established C-findings whereas β 2-microglobulin is an unspecific but valuable prognostic marker in the Global Prognostic Score for SM (GPSM).^{12,15,16}

Notwithstanding, thorough and systematic analyses on the diagnostic and prognostic value of those low-invasive and reproducible biomarkers are lacking. Based on data obtained from 2 registries (European Competence Network on Mastocytosis [ECNM] and the German Registry on Eosinophils and Mast Cells [GREM]), we therefore sought to establish various serum chemistry parameters for diagnosis and prognostication, the differentiation between ISM and AdvSM, and the differentiation between various subvariants of AdvSM.

Patients and methods

Patients

SM was diagnosed and classified according to the revised 2022 WHO/ICC classification. Patient characteristics are provided in supplemental Data (supplemental Table 1). The study design adhered to the tenets of the Declaration of Helsinki and was approved by the relevant institutional review boards of the participating centers. All patients gave written informed consent before registry participation.

ECNM registry

The ECNM registry was established in 2012 as a multidisciplinary, multinational cooperative initiative to analyze basic clinical, laboratory, and prognostic parameters in patients with cutaneous mastocytosis and SM.¹⁷⁻¹⁹ Details about the ECNM registry have been published elsewhere.¹⁹ For this analysis, we used data from a validated cohort updated in March 2019. Patients were enrolled from 26 centers in Europe (12 countries) and 1 center in the United States. We identified 2607 patients with SM with at least 1 entry regarding 1 of the following 5 serum chemistry parameters: serum tryptase, AP, β 2-microglobulin, lactate dehydrogenase (LDH), and/or albumin at time of diagnosis. Three patients with MC sarcoma and 635 patients with mastocytosis in the skin were excluded. The 2607 patients were subtyped as having ISM ($n = 1734$, 66%), BMM ($n = 327$, 13%), SSM ($n = 58$, 2%), ASM ($n = 117$, 4%), SM-AHN ($n = 326$, 13%), and MCL ($n = 45$, 2%). Availability of data and disease characteristics of the overall population and a subgroup of patients with available outcome data ($n = 685$) are presented in supplemental Tables 1 and 2.

GREM registry

The first patients were enrolled in 2009. An updated cohort in May 2019 ($n = 575$; ISM, $n = 224$, 39%; BMM, $n = 55$, 10%; SSM, $n = 23$, 4%; ASM, $n = 32$, 5%; SM-AHN, $n = 233$, 41%; and MCL, $n = 8$, 1%) was used for complementary analyses on parameters that were primarily not included in the ECNM database (AP isoenzymes, C-reactive protein [CRP], and creatinine, and vitamin B12). A patient flow diagram is provided as supplemental Figure 1.

Statistical analyses

In this retrospective study, statistical analyses were performed on clinical, laboratory, and molecular parameters that were obtained at the time of diagnosis/first referral to the servicing center and throughout the disease course. Differences in the distribution of continuous variables between categories were analyzed by the Mann-Whitney *U* test. For categorical variables, Fisher exact test was used. Overall survival (OS) analysis was considered from the date of diagnosis to date of death for any reasons (event) or last documented visit. Deaths unrelated to disease progression were observed in <0.1% of the patients. Censoring was applied for patients who did not experience death or were lost to follow-up within the study period (type-1 right-censored data). OS probabilities were calculated by the Kaplan-Meier method and compared by the log-rank test. For multivariable analysis of serum chemistry markers, a Cox proportional hazard model was used. The proportional hazards assumption was tested by the correlation of scaled Schoenfeld residuals with time.²⁰ Power calculation for the comparison of survival curves between 2 groups were performed according to Freedman.²¹ Receiver operating characteristic (ROC) analyses with calculation of the area under the ROC curve were performed to determine optimal cutoff values for the several laboratory parameters. The Youdens index was given as the summary measure of the ROC curve (sensitivity + specificity – 1). The Pearson and Spearman correlation coefficients were calculated to assess linear or monotonic relationships between 2 variables. *P* values were further adjusted by the Holm-Bonferroni method. In general, a test result with *P* < .05 has been considered as statistically significant. Statistical analyses were performed using R version 4.3.1 (R Foundation for Statistical Computing, Vienna, Austria). For graphical output, GraphPad Prism version 9 was used (GraphPad Software Inc, San Diego, CA).

The study was approved by our local ethics committee led by Harald Klüter (2020-593N), and all patients gave written informed consent.

Results

ECNM registry-based analyses

Comparison of baseline serum parameters in ISM vs AdvSM. In AdvSM, significantly higher median serum levels were observed for tryptase (164 µg/L vs 29 µg/L, *P* < .001, Mann-Whitney *U* test), AP (162 U/L vs 71 U/L, *P* < .001, Mann-Whitney *U* test), β₂-microglobulin (3.6 mg/L vs 1.8 mg/L, *P* < .001, Mann-Whitney *U* test), and LDH (181 U/L vs 168 U/L, *P* < .001, Mann-Whitney *U* test), whereas significantly lower median serum levels were observed for albumin (39 g/dL vs 44 g/dL, *P* < .001, Mann-Whitney *U* test; Figure 1; supplemental Table 1). ROC analyses identified optimal cutoff values for discrimination between ISM and AdvSM for serum tryptase at 125 µg/L, for AP at 150 U/L, for β₂-microglobulin at 2.5 mg/L, for LDH at 260 U/L, and for albumin at 34 g/dL. In 649 patients with diagnosis of SM and available outcome data, the log-rank test identified all respective markers as adverse prognostic variables regarding OS (Table 1). Assignment of 1 point each to 5 individual parameters allowed to establish a serum score through which patients at low, intermediate, and high risk can be defined (median OS 15.1 vs 3.4 vs 1.5 years, *P* < .001,

log-rank test; Figure 2A). Multivariable analysis identified β₂-microglobulin (hazard ratio [HR], 2.7; 95% confidence interval [CI], 1.4-5.4; *P* = .004), LDH (HR, 2.1; 95% CI, 1.1-4.0; *P* = .018), and albumin (HR, 3.3; 95% CI, 1.7-6.5; *P* = .001) of prognostic significance. Based on the multivariable analysis, we built an HR-weighted score and applied 1 point to patients with LDH of ≥260 U/L, and 1.5 points each to patients with β₂-microglobulin of ≥2.5 mg/L and albumin of ≥34 g/dL (Figure 2B).

Comparison of baseline serum parameters in patients with ISM, BMM, and SSM. Median serum tryptase and AP levels were significantly higher in SSM (202 µg/L and 138 U/L, respectively) and ISM (32 µg/L and 72 U/L, respectively) vs BMM (21 µg/L and 67 U/L, respectively; *P* < .001 for all comparisons, Mann-Whitney *U* test). SSM was further associated with higher β₂-microglobulin levels compared with BMM (2.3 mg/L vs 1.8 mg/L, *P* = .010, Mann-Whitney *U* test). No differences were seen regarding the median albumin level (44 g/dL in all subgroups). Surprisingly, BMM (175 U/L) showed higher LDH levels than SSM (153 U/L, *P* = .002) and ISM (167 U/L, *P* = .001, Mann-Whitney *U* test). Patients with serum tryptase levels of ≥125 µg/L were associated with an adverse median OS (15.1 vs 9.7 years, *P* = .045, log-rank test; supplemental Table 1).

Comparison of baseline serum parameters within subvariants of AdvSM. Serum tryptase levels were significantly higher in MCL (308 µg/L) than ASM (171 µg/L, *P* = .006, Mann-Whitney *U* test) and SM-AHN (135 µg/L, *P* = .002, Mann-Whitney *U* test). An elevated LDH level of ≥260 U/L was associated with the presence of an AHN (77 of 236 [33%] vs 199 of 1715 [12%]; *P* < .001, Mann-Whitney *U* test) and with a more aggressive clinical course (Table 2; Figure 3B). The median LDH levels were significantly higher in SM-AHN than in ASM (191 vs 162 U/L, *P* < .001, Mann-Whitney *U* test) (Figure 1D). Pearson correlation of LDH levels with AHN-related parameters revealed modest correlations with the absolute numbers of leukocytes (*r* = 0.37, *P* < .001; Figure 3A). Within AdvSM, patients with LDH levels of ≥260 U/L (*n* = 68), the threshold of ≥400 U/L or <400 U/L significantly affected the OS in this cohort (0.9 vs 1.9 years, *P* = .039, log-rank test; Figure 3C).

Further risk stratification in patients with IPSM-AdvSM1/2.

Risk stratification was performed by using the previously published International Prognostic Scoring System for Mastocytosis (IPSM),¹¹ a multiparametric (age of ≥60 year/<60 years, serum tryptase, ≥125 ng/mL/<125 ng/mL, leukocytes ≥16/nL/<16/nL, hemoglobin of ≥11g/dL/<11g/dL, and platelets ≥100/nL/<100/nL, with +1 point for each of these parameters, and –1 point for skin involvement resulting in a 3-tired risk model (consisting of a total score between –1 and 5 points) scoring system. In 55 patients with AdvSM with an IPSM risk score of IPSM-AdvSM1/2 (ie, –1 to 1 IPSM score points), assignment of 1 point to each of 5 serum parameters exceeding the described cutoff values (serum tryptase, AP, β₂-microglobulin, LDH, and albumin; Table 1) allowed a further risk stratification with a median OS of 9.9 vs 3.6 years, respectively (*P* = .027, log-rank test), for patients with low (0 points, *n* = 9) vs high-risk (2-4 points, *n* = 46) disease (Figure 2C).




Figure 1. ECNM. Violin plots on the distribution of various serum chemistry markers throughout the systemic mastocytosis subtypes. The *P* values refer to the Mann-Whitney *U* test. AdvSM, advanced systemic mastocytosis; ASM, aggressive systemic mastocytosis; BMM, bone marrow mastocytosis; ISM, indolent systemic mastocytosis; MCL, mast cell leukemia; SM-AHN, systemic mastocytosis with an associated hematologic neoplasm; SSM, smoldering systemic mastocytosis.

Table 1. Univariate and multivariable analysis regarding OS of 685 patients with SM enrolled within the ECNM

Characteristics	Univariate		Multivariable	
	HR (95% CI)	<i>P</i> value	HR (95% CI)	<i>P</i> value
Tryptase (n = 625) ≥/ <125 μg/L	3.4 (2.6-4.4)	<.001	1.8 (0.9-3.6)	.078
AP (n = 565) ≥/ <150 U/L	3.5 (2.7-4.4)	<.001	1.4 (0.7-3.0)	.334
β2-microglobulin (n = 158) ≥/ <2.5 mg/L	4.8 (2.9-7.9)	<.001	2.7 (1.4-5.4)	.004
LDH (n = 533) ≥/ <260 U/L	2.0 (1.5-2.7)	<.001	2.1 (1.1-4.0)	.018
Albumin (n = 508) ≤/ ≥34 g/dL	3.7 (2.7-4.9)	<.001	3.3 (1.7-6.5)	.001

Analysis included variables with receiver operating characteristic-assessed cutoffs.
AP, alkaline phosphatase; CI, confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase

Complementary GREM-based analyses

AP isoenzymes. AP isoenzymes of the liver, gallbladder, bowel, and BM were measured in 24 patients with AdvSM. Compared with standard values, increased AP isoenzymes were predominantly derived from the liver and gallbladder (Figure 4A). The most robust, yet still moderate, correlations were seen with other liver parameters (γ -glutamyl transferase, $r = 0.67$, $P < .001$; albumin, $r = -0.37$, $P < .001$; international normalized ratio, $r = -0.49$, $P < .001$ all Pearson correlation) and the (relatively) poor correlation with bone and BM parameters (BM MC infiltration, $r = 0.35$, $P < .001$, Pearson correlation; osteoporosis, $\eta = 0.09$, $P < .001$; osteolysis, $\eta = 0.16$, $P < .001$, both Spearman correlation) further substantiated the strong association between elevated AP and liver involvement/damage (Figure 4B). AP levels of ≥ 150 U/L (optimal cutoff assessed per ROC analysis) significantly affected OS (10.5 vs 2.9 years, $P < .001$, log-rank test; Figure 4C).




Figure 2.

Vitamin B12. Median vitamin B12 levels ($n = 334$) were significantly higher in AdvSM than ISM (1275 U/L vs 401 U/L, $P < .001$, Mann-Whitney U test) or SSM (353 U/L, $P < .001$, Mann-Whitney U test; Figure 5B). Elevated vitamin B12 levels correlated with markers of advanced disease (eg, high *KIT* D816V allele burden, $r = 0.45$, $P < .001$; elevated AP, $r = 0.51$, $P < .001$, both Pearson correlation; Figure 5A). The area under the curve for predicting AdvSM was 0.795 (95% CI, 0.744-0.847; $P < .001$, ROC analysis) and the optimal cutoff value was 400 U/L with a sensitivity of 82% (Youden index, 0.307; Figure 5B). In AdvSM, vitamin B12 levels of ≥ 2000 U/L conferred into worse outcome (median OS, 4.1 vs 2.6 years, $P = .037$, log-rank test; Figure 5D).

CRP. The median CRP levels ($n = 405$) were markedly increased in patients with AdvSM compared with either ISM (10.0 mg/dL vs 2.9 mg/dL, $P < .001$, Mann-Whitney U test) or SSM (3.7 mg/dL, $P < .001$, Mann-Whitney U test). Within AdvSM subvariants, the highest levels were found in SM-AHN (11 mg/dL) vs ASM (3.5 mg/dL, $P = .057$) or MCL (7.6 mg/dL, $P = .008$, Mann-Whitney U test). Concomitant infections or autoimmune diseases as confounding conditions could be excluded in 390 of 405 (96%) patients.

Creatinine-adjusted $\beta 2$ -microglobulin. Elevated $\beta 2$ -microglobulin levels were strongly associated with poor OS. Median OS was similarly affected in patients with AdvSM with $\beta 2$ -microglobulin levels of ≥ 2.5 mg/L independently whether or not the levels were adjusted for sex and age-matched serum creatinine values of $> \text{ULN}$ (not adjusted: median OS was 4.1 years vs not reached, $P < .001$; median OS was 3.9 years vs not reached, $P = .010$, log-rank test).

Discussion

Diagnosis and prognostication of ISM and AdvSM warrants application of comprehensive clinical (eg, organomegaly and weight loss), morphological (eg, BM MC infiltration and blood counts), serological (eg, tryptase and AP), and molecular (eg, *KIT* D816V and additional somatic mutations) studies.^{5,6,13,15,22-28} Because of the frequent absence of skin involvement and of typical MC mediator-related symptoms in AdvSM, many patients are misdiagnosed or the diagnosis may be significantly delayed,^{15,24} unless disease-specific features and markers, such as BM MC infiltration, serum tryptase, or *KIT* D816V are considered and comprehensively studied. Although often used as a serological marker for screening of SM, an elevated serum tryptase may also be detected in patients with kidney failure, hereditary α -tryptasemia, obesity, and other myeloid neoplasms.^{16,29-33} While there is a certain correlation

Figure 2. ECNM. (A) Kaplan-Meier estimates of overall survival (OS) in patients with systemic mastocytosis (SM) with 0 points, 1 to 2 points, vs 3 to 5 points by assignment of 1 point each to serum tryptase ≥ 125 $\mu\text{g/L}$, alkaline phosphatase (AP) ≥ 150 U/L, lactate dehydrogenase (LDH) ≥ 260 U/L, albumin ≤ 34 mg/dL, and $\beta 2$ -microglobulin ≥ 2.5 mg/L; ^apower = 1.000, ^bpower = 1.000. (B) Kaplan-Meier estimates of OS in patients with SM based on the multivariable model with 0 points, 1.5 points, vs ≥ 1.5 points by assignment of 1 point to LDH ≥ 260 U/L, and 1.5 points each to albumin ≤ 34 mg/dL and $\beta 2$ -microglobulin ≥ 2.5 mg/L; ^cpower = 1.000, ^dpower = 0.998. (C) Kaplan-Meier estimates of OS in patients weighted as International Prognostic Scoring System for Mastocytosis-advanced SM1/2 with 0 points vs ≥ 1 points. ^epower = 0.441. The P values refer to the log-rank test.

Table 2. Patients with systemic mastocytosis (ECNM) stratified according to lactate dehydrogenase levels

	LDH ≥ 260 U/L	LDH < 260 U/L	P value
Number of patients at diagnosis, n (%)	236 (12)	1715 (88)	
Age, years; median (range)	55 (18-90)	50 (5-87)	$<.001$
Male, n (%)	149 (63)	789 (46)	$<.001$
C-findings			
Hemoglobin, g/dL; median (range)	13 (4-18)	14 (4-18)	$<.001$
<10 g/dL, n (%)	44 (19)	107 (6)	$<.001$
Platelets, $\times 10^9/L$; median (range)	227 (0-958)	251 (5-893)	NS
$<100 \times 10^9/L$, n (%)	51 (22)	141 (8)	$<.001$
ANC, $\times 10^9/L$; median (range)	4 (0-9)	4 (0-76)	$<.001$
$<1 \times 10^9/L$, n (%)	7 (3)	20 (1)	.025
Alkaline phosphatase, U/L; median (range)	84 (34-1696)	77 (20-1407)	.001
>150 U/L, n (%)	58 (27)	206 (13)	$<.001$
Albumin level, g/L; median (range)	41 (16-57)	44 (20-57)	$<.001$
<34 g/L, n (%)	26 (14)	58 (4)	$<.001$
Ascites, n (%)	23 (10)	97 (6)	.020
Portal hypertension, n (%)	7 (3)	42 (3)	NS
Weight loss ($>10\%$ over last 6 months), n (%)	44 (19)	172 (10)	$<.001$
Osteolytic lesions, n (%)	7 (3)	47 (3)	NS
B-findings			
Dysmyelopoiesis, n (%)	64 (28)	206 (13)	$<.001$
BM MC infiltration, %; median (range)	15 (1-90)	10 (0-100)	NS
Serum tryptase level, $\mu g/L$; median (range)	43 (1-4530)	36 (2-4980)	NS
$>125 \mu g/L$, n (%)	59 (27)	330 (20)	.020
Splenomegaly, n (%)	65 (28)	291 (17)	$<.001$
Hepatomegaly, n (%)	58 (234)	249 (1662)	$<.001$
Lymphadenopathy, n (%)	32 (210)	148 (10)	.009
Other relevant findings			
Leukocytes, $\times 10^9/L$; median (range)	7.7 (0.6-129.3)	6.7 (1.0-97.3)	$<.001$
$>16 \times 10^9/L$, n (%)	47 (20)	55 (3)	$<.001$
Monocytes, $\times 10^9/L$; median (range)	0.5 (0.0-18.7)	0.4 (0.0-8.2)	$<.001$
$>0.8 \times 10^9/L$	44 (58)	16 (12)	$<.001$
Eosinophils, $\times 10^9/L$; median (range)	0.2 (0.0-35.0)	0.1 (0.0-18.5)	.006
$>1.5 \times 10^9/L$	17 (23)	6 (4)	$<.001$
<i>KIT</i> D816V positive, n (%)	163 (82)	1308 (88)	.029
BM MC burden in smears, %; median (range)	5 (0-88)	2 (0-100)	.041
Outcome			
Follow-up, years; median (range)	1.34 (0.0-22.3)	2.1 (0.0-28.6)	NS
Death, n (%)	65 (30)	177 (14)	$<.001$

A total of 1951 patients with systemic mastocytosis from the ECNM database were stratified according to lactate dehydrogenase levels of ≥ 260 U/L or < 260 U/L. ANC, absolute neutrophil count; BM, bone marrow; MC, mast cell; NS, not significant.

between serum tryptase levels and the subtype of SM, the differentiation between ISM, SSM, or AdvSM is not straightforward. Therefore, additional serologic parameters have been analyzed in the context of SM. One example is AP, which is typically elevated in patients with AdvSM with liver involvement. However, only a few comprehensive studies have systematically analyzed multiple serum chemistry parameters in patients with SM. Based on 2 robust patient registries, the ECNM registry and the GREM registry, we here show

that a thorough and careful investigation and interpretation of certain serum chemistry parameters substantially supports the clinician in establishing the correct diagnosis, subclassification, and prognostication of patients with SM.

Although serum tryptase levels were highest in MCL, a level below $125 \mu g/L$ in indolent phase disease was clearly associated with a more favorable outcome in patients with ISM, BMM, and SSM




Figure 3. ECNM. (A) Pearson correlation of the lactate dehydrogenase (LDH) levels with other disease parameters. *Significant P values adjusted by Holm-Bonferroni method. (B) Kaplan-Meier estimates of overall survival (OS) in patients with systemic mastocytosis (SM) stratified according to LDH levels (260-400 U/L vs $\geq$ 400 U/L); a power = 0.995. (C) Kaplan-Meier estimates of OS in patients with AdvSM according to LDH levels (260-400 U/L vs $\geq$ 400 U/L); b power = 0.720. The P values refer to the log-rank test. ANC, absolute neutrophil count; β 2MG, β 2-microglobulin; Eos, eosinophil count; Hb, hemoglobin; KIT, *KIT* D816V allele burden; MC-I, mast cell infiltration; Monos, monocyte count; Plt, platelets; WBC, white blood cells.


thus verifying the established cutoff level for differentiation between ISM and BMM.³⁴ In addition to serum tryptase, most valuable serum parameters include an elevated AP and hypoalbuminemia, which are widely included as C-findings in diagnostic criteria, recently established prognostic scoring systems, and response criteria.^{10,11,35} Based on AP isoform analyses, increased levels should be interpreted as liver involvement/damage by MC infiltration rather than as derived from bone involvement, for example, indicating osteosclerosis or osteolyzes. An elevated LDH correlated moderately with leukocytosis, monocytosis, and eosinophilia, indicating presence of an AHN.³⁶ The careful cross-assessment of serum tryptase representing the MC component, LDH (plus monocytes/eosinophils) representing the AHN component, and the *KIT* D816V variant allele frequency potentially indicative for both components may therefore allow a rapid and thorough interpretation regarding the contribution of SM or AHN to relevant organ damage such as cytopenias and clinical parameters of liver dysfunction. It offers a first estimation of a sensible use of KIT-targeted treatment.^{4,13}

Elevated vitamin B12 is a known, unspecific finding in various (myeloid) neoplasms.³⁷⁻³⁹ ROC analyses revealed that a cutoff level of $\geq$ 400 U/L (in the absence of supplementation) is indicative of AdvSM, and that a level of $\geq$ 2000 U/L correlated with adverse

prognosis allowing its complimentary use for assessment of response and progression. Significant weight loss may result from malabsorption and malnutrition but also from chronic inflammation, and it was regularly accompanied by hypoalbuminemia and elevated CRP, with median CRP values being higher in AdvSM than in ISM (GREM cohort). Of interest, disease-associated symptoms such as night sweats or weight loss as well as the aforementioned serum chemistry parameters, responded significantly on targeted treatment with midostaurin or avapritinib in most patients.⁴⁰⁻⁴³

Several prognostic scoring systems have recently been established for patients with SM and its subtypes. Whereas some scores are based on clinical parameters with inclusion of serum chemistry parameters, for example, tryptase (IPSM), AP (GPSM), and β 2-microglobulin (GPSM), and the WHO classification, others are based on additional molecular abnormalities. By now, no serum chemistry-specific score has been developed. In this study, assignment of 1 point each to 5 individual serum parameters based on ROC analyses defined cutoff values for tryptase, AP, β 2-microglobulin, LDH, and albumin allowed to create a serum score with differentiation between patients with low-, intermediate-, and high-risk SM (median OS, 15.1 vs 3.4 vs 1.5 years, respectively, $P < .001$). Further adjunction of serum markers in patients with IPSM AdvSM1/2-

Figure 4. GEM. (A) Violin plots on the distribution of the alkaline phosphatase (AP) subtypes in 24 patients with advanced systemic mastocytosis (AdvSM). (B) Pearson and Spearman correlations of the AP levels with other (liver and bone marrow) specific parameters. *Significant *P* values adjusted by Holm-Bonferroni method. (C) Kaplan-Meier estimates of overall survival in patients with AdvSM stratified according to AP levels ≥ 150 U/L <150 U/L. ^apower = 0.974. Alb, albumin; ASAT, aspartate aminotransferase; Bili, bilirubin; MC-I, BM mast cell infiltration; O.lysis, osteolysis; O.poris, osteoporosis.



weighted disease identified patients at higher risk in these otherwise favorable AdvSM subgroups. However, given the limited power of the log-rank test, a possible overestimation of the observed effect size could not be excluded with complete certainty, necessitating verification in a larger, higher-powered analysis. Unfortunately, information on $\beta 2$ -microglobulin was missing in 78% of patients from the ECNM cohort. We therefore strongly recommend the routine assessment of $\beta 2$ -microglobulin in the diagnostic workup of SM.

Given the unavailability of molecular analyses for non-hematologists and the multidisciplinary management of patients with SM by dermatologists, gastroenterologists, and immunologists/endocrinologists, it is of substantial relevance to identify easily available “red flags” pointing out on a more thorough diagnostic workup, for example, BM biopsy and molecular analyses, and the potential need for more aggressive treatment.




Figure 5. GREM. (A) Pearson correlation of the vitamin B12 levels with other disease specific parameters. *Significant P values adjusted by Holm-Bonferroni method. (B) Receiver operating characteristic-curve for optimal cutoff assessment regarding diagnosis of indolent systemic mastocytosis (ISM) vs advanced SM (AdvSM). (C) Kaplan-Meier estimates of overall survival (OS) in patients with SM according to vitamin B12 levels (<800 U/L vs ≥800-1800 U/L vs ≥1800 U/L); ^apower = 0.948, ^bpower = 0.627. (D) Kaplan-Meier estimates of OS in patients with AdvSM (≥2000 U/L vs <2000 U/L); ^cpower = 0.586. The P values refer to the log-rank test. ANC, absolute neutrophil count; β2MG, β2-microglobulin; Eos, eosinophil count; Hb, hemoglobin; KIT, *KIT* D816V allele burden; MC-I, mast cell infiltration; Monos, monocyte count; Plt, platelets; WBC, white blood cells.

We conclude that beside its value for diagnosis according to WHO/ICC (albumin, tryptase, and AP) classifications and various risk scoring systems (β2-microglobulin and AP), routine serum chemistry should also include vitamin B12, LDH, and CRP, individually contributing to improved diagnosis, subclassification, and prognostication. Those easily accessible parameters combine advantages regarding availability, reliability, and observer-objectivity, and may therefore serve as feasible tools in the clinical practice of medical doctors from all specialties involved in the management of patients with SM.

Acknowledgments

J.L., A.R., and J.S. are supported by the Wilhelm Sander-Stiftung (grant no. 2023.120.1). P.V. was supported by the Austrian Science Fund (Fonds zur Förderung der wissenschaftlichen Forschung), grant numbers: F4704-B20 and P32470-B. E.H. was supported by the Austrian Science Fund (Fonds zur Förderung der wissenschaftlichen Forschung): P32470-B. M.N. and A.G. were supported by the Medical University of Gdańsk, grant ST 02-0141/07/231. K.H. was supported by the Swiss National Science Foundation, grant number: 310030_207705. M.L. was supported by the Medical University of Gdańsk, grant 02-10022/0000701. V.S. is a senior clinical researcher of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (1804518N). L.M. was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy (Investigator grant no. 20125; AIRC

5×1000 project no. 21267); and Cancer Research UK, Fundacion Cientifica de la Asociacion Espanola Contra el Cancer, and AIRC under the International Accelerator Award Program (project no. C355/A26819 and no. 22796).

Authorship

Contribution: J.L., W.R.S., P.V., A.R., and J.S. conceptualized and designed the study; all authors provided study materials, and collected and assembled data; J.L., A.R., and J.S. analyzed and interpreted data; and all authors wrote the manuscript and approved the final version of the manuscript and are accountable for all aspects of the work.

Conflict-of-interest disclosure: The authors declare no conflict of interest within this study and declare the following conflict of interests outside of this study. D.C. received consulting fees from Blueprint Medicines, Novartis, Pfizer and BeiGene, honoraria from Blueprint Medicines, Novartis and AstraZeneca and travel support from Amgen and Janssen. H.N.G.O.E. serves on the advisory board of, and received honoraria from, Blueprint Medicines. R.Z. serves on the advisory board of, and received honoraria from, Blueprint Medicines, Novartis, and Cogent Biosciences. P.B. serves on the advisory board of, and received honoraria from, Blueprint Medicines and Novartis. K.S. serves on the advisory board of, and received honoraria from, Blueprint Medicines and Novartis; and is a member of the study steering committee for the CGT9486 Study of Cogent Biosciences. C.E. serves on the

advisory board of, and received honoraria from, Blueprint Medicines and Gilead. K.B. serves on the advisory board of, and received honoraria from, Blueprint Medicines and Novartis. V.S. serves on the advisory board of Blueprint Medicines and Novartis. K.H. received research funding from ThermoFisher; and serves on the advisory board of, and received honoraria from ALK-Abello, Allergopharma, Blueprint, Deciphera, Leo Pharma, Menarini, Novartis, Pfizer, Sanofi, Takeda, and ThermoFisher. M.T. serves on the advisory board of, and received honoraria from, Blueprint Medicines, Novartis, and Cogent. J.G. received research grants (funds for administration of clinical trials) from Novartis, Blueprint Medicines, and Cogent Biosciences; serves on the advisory board of, and received honoraria from, Blueprint Medicines, Novartis, Deciphera, and Cogent Biosciences; and received reimbursement of travel expenses from Novartis and Blueprint Medicines. M.A. received research grants from Blueprint Medicines; and serves on the advisory board of, and received honoraria from, AB Science, Blueprint Medicines, Novartis, and ThermoFisher. H.C.K.-N. served as a nonpaid independent monitoring committee member of the avapritinib study. J.P. serves on the advisory board of, and received honoraria from, Blueprint Medicines, Novartis, and Deciphera; is a member of the study steering committee for the HARBOR Study of BLU-263 for indolent systemic mastocytosis. W.R.S. serves on the advisory board of, and received honoraria from, AbbVie, Novartis, Bristol Myers Squibb/Celgene, Pfizer, Teva, and Stemline. P.V. serves on the advisory board of, and received honoraria from, Novartis,

Blueprint, Bristol Myers Squibb/Celgene, Pfizer, Incyte, AOP Orphan, Cogent, and Stemline. A.R. is a member of the study steering committee for the global trial of midostaurin in AdvSM (Novartis); is a member of the response adjudication committee for studies of avapritinib in AdvSM (Blueprint Medicines), and the study steering committee for the phase 2 trial of ripretinib in AdvSM (Deciphera Pharmaceuticals); has received funding for the conduct of these trials; and has received honoraria and reimbursement of travel expenses from Novartis, Blueprint Medicines, and Deciphera Pharmaceuticals. J.S. serves on the advisory board of, and received honoraria from, Blueprint Medicines and Novartis. The remaining authors declare no competing financial interests.

ORCID profiles: J.L., [0000-0003-0767-1504](https://orcid.org/0000-0003-0767-1504); D.C., [0000-0003-2839-5983](https://orcid.org/0000-0003-2839-5983); H.N.G.O.E., [0000-0003-2844-2196](https://orcid.org/0000-0003-2844-2196); M.L., [0000-0002-6967-1393](https://orcid.org/0000-0002-6967-1393); E.H., [0000-0001-7409-4204](https://orcid.org/0000-0001-7409-4204); N.v.B., [0000-0001-9593-8947](https://orcid.org/0000-0001-9593-8947); L.M., [0000-0002-1460-1611](https://orcid.org/0000-0002-1460-1611); F.C., [0000-0003-3583-0816](https://orcid.org/0000-0003-3583-0816); K.B., [0000-0002-2775-3681](https://orcid.org/0000-0002-2775-3681); A.Z., [0000-0001-9313-6588](https://orcid.org/0000-0001-9313-6588); C.B., [0000-0002-7368-1068](https://orcid.org/0000-0002-7368-1068); K.H., [0000-0002-4595-8226](https://orcid.org/0000-0002-4595-8226); M.T., [0000-0001-7318-2093](https://orcid.org/0000-0001-7318-2093); H.C.K.-N., [0000-0003-2617-9427](https://orcid.org/0000-0003-2617-9427); J.P., [0000-0001-6316-3112](https://orcid.org/0000-0001-6316-3112); P.V., [0000-0003-0456-5095](https://orcid.org/0000-0003-0456-5095).

Correspondence: Juliana Schwaab, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany; email: juliana.schwaab@medma.uni-heidelberg.de.

References

1. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. *Leuk Res*. 2001;25(7):603-625.
2. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. *Blood*. 2017;129(11):1420-1427.
3. Valent P, Akin C, Nedoszytko B, et al. Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. *Int J Mol Sci*. 2020;21(23):9030.
4. Reiter A, George TI, Gotlib J. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. *Blood*. 2020;135(16):1365-1376.
5. Erben P, Schwaab J, Metzgeroth G, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. *Ann Hematol*. 2014;93(1):81-88.
6. Jawhar M, Schwaab J, Schnittger S, et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. *Leukemia*. 2015;29(5):1115-1122.
7. Kristensen T, Vestergaard H, Møller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. *J Mol Diagn*. 2011;13(2):180-188.
8. Arock M, Sotlar K, Akin C, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. *Leukemia*. 2015;29(6):1223-1232.
9. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. *Blood*. 2009;113(23):5727-5736.
10. Jawhar M, Schwaab J, Alvarez-Twose I, et al. MARS: mutation-adjusted risk score for advanced systemic mastocytosis. *J Clin Oncol*. 2019;37:2846-56.
11. Sperr WR, Kundi M, Alvarez-Twose I, et al. International Prognostic Scoring System for Mastocytosis (IPSM): a retrospective cohort study. *Lancet Haematol*. 2019;6(12):e638-e649.
12. Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M, et al. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. *Lancet Haematol*. 2021;8(3):e194-e204.
13. Lübke J, Schwaab J, Naumann N, et al. Superior efficacy of midostaurin over cladribine in advanced systemic mastocytosis: a registry-based analysis. *J Clin Oncol*. 2022;40:1783-1794.
14. Jawhar M, Schwaab J, Meggendorfer M, et al. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. *Haematologica*. 2017;102(6):1035-1043.

15. Schwaab J, Cabral do O, Hartmann N, Naumann N, et al. Importance of adequate diagnostic work-up for correct diagnosis of advanced systemic mastocytosis. *J Allergy Clin Immunol Pract*. 2020;8(9):3121-3127.e1.
16. Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. *Hemasphere*. 2021; 5(11):e646.
17. Valent P, Arock M, Bischoff SC, et al. The European Competence Network on Mastocytosis (ECNM). *Wien Klin Wochenschr*. 2004;116(19-20): 647-651.
18. Valent P, Arock M, Bonadonna P, et al. European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. *Wien Klin Wochenschr*. 2012;124(23-24):807-814.
19. Valent P, Oude Elberink JNG, Gorska A, et al; Study Group of the European Competence Network on Mastocytosis ECNM. The data registry of the European Competence Network on Mastocytosis (ECNM): set up, projects, and perspectives. *J Allergy Clin Immunol Pract*. 2019;7(1):81-87.
20. Schoenfeld D. Partial residuals for the proportional hazards regression model. *Biometrika*. 1982;69(1):239-241.
21. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. *Stat Med*. 1982;1(2):121-129.
22. Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. *Blood*. 2013;122(14):2460-2466.
23. Jawhar M, Schwaab J, Schnittger S, et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. *Leukemia*. 2016;30(1):136-143.
24. Jawhar M, Schwaab J, Horny HP, et al. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. *Eur J Clin Invest*. 2016; 46(5):392-397.
25. Jawhar M, Schwaab J, Hausmann D, et al. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. *Leukemia*. 2016;30(12):2342-2350.
26. Naumann N, Lübke J, Shomali W, et al. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations. *Br J Haematol*. 2021;194:344-354.
27. Naumann N, Lübke J, Baumann S, et al. Adverse prognostic impact of the KIT D816V transcriptional activity in advanced systemic mastocytosis. *Int J Mol Sci*. 2021;22(5):2562.
28. Hoermann G, Sotlar K, Jawhar M, et al. Standards of genetic testing in the diagnosis and prognostication of systemic mastocytosis in 2022: recommendations of the EU-US Cooperative Group. *J Allergy Clin Immunol Pract*. 2022;10(8):1953-1963.
29. Aberer E, Savić S, Brettertkieber A, Reiter H, Berghold A, Aberer W. Disease spectrum in patients with elevated serum tryptase levels. *Australas J Dermatol*. 2015;56(1):7-13.
30. Pucar PA, Hawkins CA, Randall KL, Li C, McNaughton E, Cook MC. Comparison of enzyme-linked immunosorbent assay and rapid chemiluminescent analyser in the detection of myeloperoxidase and proteinase 3 autoantibodies. *Pathology*. 2017;49(4):413-418.
31. Lyons JJ. Hereditary alpha tryptasemia: genotyping and associated clinical features. *Immunol Allergy Clin North Am*. 2018;38(3):483-495.
32. Sperr WR, El-Samahi A, Kundi M, et al. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. *Eur J Clin Invest*. 2009;39(10):914-923.
33. Vos BJ, van der Veer E, van Voorst Vader PC, et al. Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects. *J Allergy Clin Immunol*. 2015;135(3):792-798.
34. Zanotti R, Bonifacio M, Lucchini G, et al. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European Competence Network on mastocytosis. *Leukemia*. 2022;36(2):516-524.
35. Pardanani A, Shah S, Mannelli F, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. *Blood Adv*. 2018; 2(21):2964-2972.
36. Kluin-Nelemans HC, Reiter A, Illerhaus A, et al. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. *Leukemia*. 2020;34(4):1090-1101.
37. Gavars D, Perminov D, Tauckels E, Lindenberg A, Auce A, Lejniece S. Association of elevated vitamin B(12) with oncohematological diseases in a cohort of 79,524 patients from Latvia. *Exp Oncol*. 2019;41(4):357-362.
38. Arendt JFH, Sørensen HT, Horsfall LJ, Petersen I. Elevated vitamin B12 levels and cancer risk in UK primary care: a THIN Database Cohort Study. *Cancer Epidemiol Biomarkers Prev*. 2019;28(4):814-821.
39. Arendt JF, Pedersen L, Nexø E, Sørensen HT. Elevated plasma vitamin B12 levels as a marker for cancer: a population-based cohort study. *J Natl Cancer Inst*. 2013;105(23):1799-1805.
40. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. *N Engl J Med*. 2016;374(26): 2530-2541.
41. Gotlib J, Kluin-Nelemans HC, Akin C, Hartmann K, Valent P, Reiter A. Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. *Expert Opin Biol Ther*. 2021;21(4):487-498.
42. DeAngelo DJ, Radia DH, George TI, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. *Nat Med*. 2021;27(12):2183-2191.
43. Gotlib J, Reiter A, Radia DH, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. *Nat Med*. 2021;27(12):2192-2199.